FreedomWorks Foundation Launches MFN Drug Price Controls Scorecard

WASHINGTON, D.C. — FreedomWorks Foundation today announces the launch of its Most Favored Nations (MFN) Drug Price Controls Scorecard. The Scorecard notes the prevalence of four key indicators related to an MFN drug price control proposal: reduced access to meds, long wait times for health services, a single payer system, and equipment shortages. The preponderance of these characteristics in 17 other developed countries is noted on the scorecard.

Adam Brandon, FreedomWorks President, commented:

“Drug price controls, particularly in the form of the administration’s latest MFN proposal, will restrict Americans’ access to prescription drugs, lead to increased wait times and equipment shortages, and set us on the path to a socialized single payer system. FreedomWorks Foundation’s scorecard clearly lays out the issues associated with an MFN proposal. While the rising cost of prescription drugs is a major problem, we cannot allow the federal government to arbitrarily set prices. The rising cost of prescription drugs cannot be fixed by some ‘silver bullet’ remedy such as an MFN proposal, and we encourage the administration to reconsider and adopt free market alternatives.”